126 related articles for article (PubMed ID: 23473990)
1. The oncofetal protein IMP3: a novel biomarker and triage tool for premalignant atypical endometriotic lesions.
Vercellini P; Cribiù FM; Del Gobbo A; Carcangiu ML; Somigliana E; Bòsari S
Fertil Steril; 2013 Jun; 99(7):1974-9. PubMed ID: 23473990
[TBL] [Abstract][Full Text] [Related]
2. Clear cell carcinomas of the ovary: a mono-institutional study of 73 cases in China with an analysis of the prognostic significance of clinicopathological parameters and IMP3 expression.
Bi R; Shen X; Zhang W; Cheng Y; Feng Z; Cai X; Yang W
Diagn Pathol; 2016 Feb; 11():17. PubMed ID: 26837693
[TBL] [Abstract][Full Text] [Related]
3. Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?
Samartzis EP; Samartzis N; Noske A; Fedier A; Caduff R; Dedes KJ; Fink D; Imesch P
Mod Pathol; 2012 Jun; 25(6):885-92. PubMed ID: 22301703
[TBL] [Abstract][Full Text] [Related]
4. The utility of PAX8 and IMP3 immunohistochemical stains in the differential diagnosis of benign, premalignant, and malignant endocervical glandular lesions.
Danialan R; Assaad M; Burghardt J; Newcomb P; Cartun RW; Mandavilli S
Gynecol Oncol; 2013 Aug; 130(2):383-8. PubMed ID: 23618832
[TBL] [Abstract][Full Text] [Related]
5. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
6. S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy.
Levy M; Lin F; Xu H; Dhall D; Spaulding BO; Wang HL
Hum Pathol; 2010 Sep; 41(9):1210-9. PubMed ID: 20382408
[TBL] [Abstract][Full Text] [Related]
7. Prognostic importance of atypical endometriosis with architectural hyperplasia versus cytologic atypia in endometriosis-associated ovarian cancer.
Ñiguez Sevilla I; Machado Linde F; Marín Sánchez MDP; Arense JJ; Torroba A; Nieto Díaz A; Sánchez Ferrer ML
J Gynecol Oncol; 2019 Jul; 30(4):e63. PubMed ID: 31074246
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of IMP3 and p53 in inflammatory lesions and neoplastic lesions of the gastric mucosa.
Strehl JD; Hoegel J; Hornicek I; Hartmann A; Riener MO
Int J Clin Exp Pathol; 2014; 7(5):2091-101. PubMed ID: 24966917
[TBL] [Abstract][Full Text] [Related]
9. Atypical epithelial changes and mutant p53 gene expression in ovarian endometriosis.
Bayramoğlu H; Düzcan E
Pathol Oncol Res; 2001; 7(1):33-8. PubMed ID: 11349218
[TBL] [Abstract][Full Text] [Related]
10. Expression of insulin-like growth factor II mRNA binding protein 3 (IMP3) in enchondroma and chondrosarcoma.
Shooshtarizadeh T; Nazeri A; Zare-Mirzaie A; Movahedinia S
Pathol Res Pract; 2016 Apr; 212(4):335-9. PubMed ID: 26948096
[TBL] [Abstract][Full Text] [Related]
11. Chromosome 12p abnormalities and IMP3 expression in prepubertal pure testicular teratomas.
Cornejo KM; Cheng L; Church A; Wang M; Jiang Z
Hum Pathol; 2016 Mar; 49():54-60. PubMed ID: 26826410
[TBL] [Abstract][Full Text] [Related]
12. IMP3 is a novel biomarker to predict metastasis and prognosis of tongue squamous cell carcinoma.
Li HG; Han JJ; Huang ZQ; Wang L; Chen WL; Shen XM
J Craniofac Surg; 2011 Nov; 22(6):2022-5. PubMed ID: 22067851
[TBL] [Abstract][Full Text] [Related]
13. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
Shi M; Fraire AE; Chu P; Cornejo K; Woda BA; Dresser K; Rock KL; Jiang Z
Am J Surg Pathol; 2011 Jun; 35(6):878-82. PubMed ID: 21566519
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical evaluation of epithelial antigen Ber-Ep4 and CD10: new markers for endometriosis?
Capobianco G; Wenger JM; Marras V; Cosmi E; Ambrosini G; Dessole M; Cherchi PL
Eur J Gynaecol Oncol; 2013; 34(3):254-6. PubMed ID: 23967557
[TBL] [Abstract][Full Text] [Related]
15. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts.
Nezhat F; Cohen C; Rahaman J; Gretz H; Cole P; Kalir T
Cancer; 2002 Jun; 94(11):2935-40. PubMed ID: 12115382
[TBL] [Abstract][Full Text] [Related]
16. p53 protein expression in putative precursor lesions of epithelial ovarian cancer.
Hutson R; Ramsdale J; Wells M
Histopathology; 1995 Oct; 27(4):367-71. PubMed ID: 8847068
[TBL] [Abstract][Full Text] [Related]
17. MRI of endometriotic cysts in association with ovarian carcinoma.
Tanaka YO; Okada S; Yagi T; Satoh T; Oki A; Tsunoda H; Yoshikawa H
AJR Am J Roentgenol; 2010 Feb; 194(2):355-61. PubMed ID: 20093596
[TBL] [Abstract][Full Text] [Related]
18. Comparative immunohistochemical studies of endometriosis lesions and endometriotic cysts.
Nezhat FR; Kalir T
Fertil Steril; 2002 Oct; 78(4):820-4. PubMed ID: 12372462
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor II messenger RNA-binding protein-3 is an indicator of malignant phyllodes tumor of the breast.
Takizawa K; Yamamoto H; Taguchi K; Ohno S; Tokunaga E; Yamashita N; Kubo M; Nakamura M; Oda Y
Hum Pathol; 2016 Sep; 55():30-8. PubMed ID: 27137988
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of IMP3 between male and female mature teratomas--immunohistochemical evidence of malignant nature.
Goodman S; Zhang L; Cheng L; Jiang Z
Histopathology; 2014 Oct; 65(4):483-9. PubMed ID: 24605891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
